← FDA DRUG APPROVALS

FDA ANDA · ANDA072508

METHYLDOPA AND HYDROCHLOROTHIAZIDE

Sponsor: DAVA PHARMS INC

APPLICATION
ANDA072508
TYPE
ANDA
ORIGINAL APPROVAL
1989-06-02
LATEST ACTION
1998-04-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

METHYLDOPA AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, METHYLDOPA 250MG · TABLET · ORAL

Approval history

1998-04-14Labeling · Supplement 10AP
1997-06-23Labeling · Supplement 9AP
1996-02-21Manufacturing (CMC) · Supplement 7AP
1996-02-21Manufacturing (CMC) · Supplement 8AP
1995-01-13Labeling · Supplement 6AP
1993-04-14Labeling · Supplement 5AP
1992-11-16Manufacturing (CMC) · Supplement 3AP
1992-11-16Manufacturing (CMC) · Supplement 4AP
1992-04-02Labeling · Supplement 2AP
1991-03-06Manufacturing (CMC) · Supplement 1AP
1989-06-02OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →